Trends and type of Mycoplasma genitalium resistance mutations in dermatovenerologic patients in the Moscow region

Kisina V.I.; Romanova I.V.; Gushchin A.E.

doi:https://doi.org/10.17116/klinderma202221061784

Close metadata

Abstract:

Mycoplasma genitalium refers to sexually transmitted infections and can cause various complications that negatively affect reproductive health. Effective treatment of M. genitalium infection is challenging due to actively emerging resistance to the antibiotics usually used. Studies showed that treatment failures of M. genitalium infection might be due to infection with mutant strains or de novo mutations during inadequate therapy.

OBJECTIVE

To study trends and types of Mycoplasma genitalium resistance mutations in dermatovenerologic patients in the Moscow region.

MATERIALS AND METHODS

The object of the study was 645 isolates of M. genitalium isolated from patients who applied for medical care at MRCDC branches and outpatient records of 454 patients with M. genitalium infection.

RESULTS AND CONCLUSION

The results of the study demonstrated the need to monitor health care practices in patients with M. genitalium infection in the Moscow region. From 2014 to 2018, an increase in the detection rate of M. genitalium with resistance to fluoroquinolones 1.9-fold and to macrolides 2.6-fold was observed. Analysis of outpatient records of patients with M. genitalium infection showed that the management of patients with M. genitalium infection is often non-compliant with current evidence-based guidelines. The results indicate the need to introduce approaches to detect M. genitalium mutations causing resistance to macrolides and fluoroquinolones to select optimal treatment regimens and reduce the resistance rate of M. genitalium.

Keywords:

M.genitalium infection

clinical symptoms

resistance

mutations

treatment

Authors:

Kisina V.I.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology

ORCID: 0000-0002-3761-9400

Romanova I.V.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology

ORCID: 0000-0001-9702-4655

Gushchin A.E.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology

ORCID: 0000-0002-0399-1167

Received:

20.12.2021

Accepted:

19.09.2022

Close metadata

References:

Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: From Chrysalis to multicolored butterfly. Clin Microbiol Rev. 2011;24(3):498. https://doi.org/10.1128/cmr.00006-11
Jensen JS, Bradshaw C. Management of Mycoplasma genitalium infections — can we hit a moving target? BMC Infect Dis. 2015;15:343. https://doi.org/10.1186/s12879-015-1041-6
Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium Infection and Female Reproductive Tract Disease: A Meta-analysis. Clin Infect Dis. 2015;61(3):418. https://doi.org/10.1093/cid/civ312
Potekaev NN, Kisina VI, Romanova IV, Guschin AE, Polevschikova SA. Current status of Mycoplasma genitalium infection. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2018;17(3):12-21. (In Russ.). https://doi.org/10.17116/klinderma201817312
Mahlangu MP, Müller EE, Venter J, et al. The Prevalence of Mycoplasma genitaliumand Association With Human Immunodeficiency Virus Infection in Symptomatic Patients, Johannesburg, South Africa, 2007–2014. Sex Transm Dis. 2019;46(6):395. https://doi.org/10.1097/olq.0000000000000984
Mavedzenge SN, Van der Pol B, Weiss HA, et al. The association between Mycoplasma genitaliumand HIV-1 acquisition in African women. AIDS. 2012;26(5):617. https://doi.org/10.1097/qad.0b013e32834ff690
Ong JJ, Magooa MP, Chikandiwa A, et al. Clinical characteristics of Mycoplasma genitalium and the Usefulness of Syndromic Management Among Women Living With Human Immunodeficiency Virus. Sex Transm Dis. 2019;46(12):801. https://doi.org/10.1097/olq.0000000000001054
Horner P, Ingle SM, Garrett F, et al. Which azithromycin regimen should be used for treating Mycoplasma genitalium? A meta-analysis. Sex Transm Infect. 2018;94(1):14. https://doi.org/10.1136/sextrans-2016-053060
Read T, Fairley CK, Tabrizi SN, et al. Azithromycin 1.5g Over 5 Days Compared to 1g Single Dose in Urethral Mycoplasma genitalium: Impact on Treatment Outcome and Resistance. Clin Infect Dis. 2017;64(3):250. https://doi.org/10.1093/cid/ciw719
Lau A, Bradshaw CS, Lewis D, et al. The Efficacy of Azithromycin for the Treatment of Genital Mycoplasma genitalium: A Systematic Review and Meta-analysis. Clin Infect Dis. 2015;61(9):1389. https://doi.org/10.1093/cid/civ644
Machalek DA, Tao Y, Shilling H, et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: A systematic review and meta-analysis. Lancet Infect Dis. 2020:S1473-3099(20)30154-30157. https://doi.org/10.1016/s1473-3099(20)30154-7
Read T, Murray GL, Danielewski JA, et al. Symptoms, Sites, and Significance of Mycoplasma genitalium in Men Who Have Sex with Men. Emerg Infect Dis. 2019;25(4):719. https://doi.org/10.3201/eid2504.181258
Murray GL, Bodiyabadu K, Danielewski J, et al. Moxifloxacin and Sitafloxacin Treatment Failure in Mycoplasma genitalium Infection: Association with parC Mutation G248T (S83I) and Concurrent gyrA Mutations. J Infect Dis. 2020;221(6):1017. https://doi.org/10.1093/infdis/jiz550
Bradshaw CS, Jensen JS, Tabrizi SN, et al. Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis. 2006;12(7):1149. https://doi.org/10.3201/eid1207.051558
Couldwell DL, Tagg KA, Jeoffreys NJ, et al. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int J STD AIDS. 2013;24(10):822. https://doi.org/10.1177/0956462413502008
Li Y, Le WJ, Li S, et al. Meta-analysis of the efficacy of moxifloxacin in treating Mycoplasma genitalium infection. Int J STD AIDS. 2017;28(11):1106. https://doi.org/10.1177/0956462416688562
Read T, Fairley CK, Murray GL, et al. Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation. Clin Infect Dis. 2019;68(4):554. https://doi.org/10.1093/cid/ciy477
Zubareva LM, Edelstein IA, Rudneva NS. The rates of mutations associated with macrolide resistance in Mycoplasma genitalium among patients with non-gonococcal sexually transmitted infections in Smolensk and Tula. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(4):330-339. (In Russ.). https://doi.org/10.36488/cmac.2019.4.330-339
Shipitsyna E Rumyantseva T, et al. Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia. PLoSOne. 2017;12(4):e0175763. https://doi.org/10.1371/journal.pone.0175763
Romanova IV, Kisina VI, Khayrullina GA, Frigo NV, Zhukova OV, Guschin AE. The prevalence and type of M. genitalium mutations in dermatovenerological patients of the Moscow region for the period 2014-2018. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2020;19(1):7-12. (In Russ.). https://doi.org/10.17116/klinderma2020190117
Deguchi T, Maeda S, et al. Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. J Antimicrob Chemother. 2001;48(5):742-744. https://doi.org/10.1093/jac/48.5.742
Jensen JS, Bradshaw CS, et al. Azithromycin treatment failure in Mycoplasma genitalium — positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis. 2008;47:1546-1553. https://doi.org/10.1086/593188
Yamaguchi, Y. Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium. Antimicrob Agents Chemother. 2013; 57(4):1772-1776. https://doi.org/10.1128/aac.01956-12
Manhart L, Broad JM, Golden MR. Mycoplasma genitalium: Should We Treat and How? Clin Infect Dis. 2011;53(3):129-142.
Potekaev NN, Kisina VI, Romanova IV, Guschin AE, Zhukova OV. Results of a survey of dermatovenerologists in the Moscow region on the problem of Mycoplasma genitalium infection. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2018;17(2):50-56. (In Russ.). https://doi.org/10.17116/klinderma201817250-56
Federal’nye klinicheskie rekomendatsii. Dermatovenerologiya 2015. Bolezni kozhi. Infektsii, peredavaemye polovym putem. 5-e izd., pererab. i dop. M.: Delovoi ekspress; 2016. (In Russ.).
Gesink DC, et al. Mycoplasma genitalium presence, resistance and epidemiology in Greenland. Int J Circumpolar Health. 2012;16:1-8. https://doi.org/10.3402/ijch.v71i0.18203
Salado-Rasmussen K, Jensen JS. Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey. Clin Infect Dis. 2014;59:24-30. https://doi.org/10.1093/cid/ciu217
Martens L, Kuster S, et al. Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014–2017. Emerg Infect Dis. 2019; 25(7):1297-1303. https://doi.org/10.3201/eid2507.181556
Bissessor M, Tabrizi SN, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis. 2015;60(8):1228-1236. https://doi.org/10.1093/cid/ciu1162
Trembizki E, Buckley C, et al. High levels of macrolide-resistant Mycoplasma genitalium in Queensland, Australia. J Med Microbiol. 2017;66(10):1451-1453. https://doi.org/10.1099/jmm.0.000584
Chrisment D, et al. Detection of macrolide resistance in Mycoplasma genitalium in France. J Antimicrob Chemother. 2012;67(11):2598-2601. https://doi.org/10.1093/jac/dks263
Barkham T, Wen Ying Tang, et al. Macrolide Resistance in Mycoplasma genitalium in Singapore. Open Forum Infect Dis. 2017;4:104. https://doi.org/10.1093/ofid/ofx163.093
Coorevits L, Traen A, et al. Macrolide resistance in Mycoplasma genitalium in Female Sex Workers, Belgium. J Glob Antimicrob Resist. 2018;12:149-152. https://doi.org/10.1016/j.jgar.2017.09.018
Unemo M, et al. Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016. Clin Microbiol Infect. 2018;24:533-539. https://doi.org/10.1016/j.cmi.2017.09.006
Gesink D, et al. Mycoplasma genitalium in Toronto, Ont: Estimates of prevalence and macrolide resistance. CanFam Physician. 2016;62(2):96-101.
Pitt R, Woodford N, Alexander S. Detection of markers predictive of macrolide and fluoroquinolone resistance in Mycoplasma genitalium from patients attending sexual health services in England. Sex Transm Infect. 2017; 94(1):9-13. https://doi.org/10.1136/sextrans-2017-053164
Barberá MJ, Fernández-Huerta M, et al. Mycoplasma genitalium Macrolide and Fluoroquinolone Resistance: Prevalence and Risk Factors Among a 2013–2014 Cohort of Patients in Barcelona, Spain. Sex Transm Dis. 2017; 8:457-462. https://doi.org/10.1097/olq.0000000000000631
Bachmann LH, Kirkcaldy RD, Geisler WM, et al. Prevalence of Mycoplasma genitalium infection, antimicrobial resistance mutations and symptom resolution following treatment of urethritis. Clin Infect Dis. 2020;71:e624-32. https://doi.org/10.1093/cid/ciaa293
Wujian Ke, Dongling Li, Lai Sze Tso, et al. Macrolide and fluoroquinolone associated mutations in Mycoplasma genitalium in a retrospective study of male and female patients seeking care at a STI Clinic in Guangzhou, China, 2016–2018. BMC Infect Dis. 2020;20:950. https://doi.org/10.1186/s12879-020-05659-3
Rasmus Desdorf, Niles Moller Andersen, Ming Chen. Mycoplasma genitalium prevalence and macrolide resistance-associated mutations and coinfection with Chlamydia trachomatis in Southern Jutland, Denmark. APMIS. 2021;129(12):706-710. Epub 2021 Oct 24. https://doi.org/10.1111/apm.13174
Guschin A et al. Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin. BMC Infect Dis. 2015;3.15:40. https://doi.org/10.1186/s12879-015-0781-7
Naokatsu Ando, Daisuke Mizushima, et al. High prevalence of circulating dual-class resistant Mycoplasma genitalium in asymptomatic MSM in Tokyo, Japan. JAC Antimicrob Resist. 2021;3(2):dlab091. https://doi.org/10.1093/jacamr/dlab091
Dumke R, Spornraft-Ragaller P. Antibiotic Resistance and Genotypes of Mycoplasma genitalium during a Resistance-Guided Treatment Regime in a German University Hospital. Antibiotics. 2021;10(8):962. https://doi.org/10.3390/antibiotics10080962
Björnelius E, Anagrius C, Bojs G, Carlberg H, Johannisson G, Johansson E. Antibiotic treatment of symptomatic Mycoplasma genitalium infection in Scandinavia: a controlled clinical trial. Sex Transm Infect. 2008;84(1):72-76.
Mena LA, Mroczkowski TF, Nsuami M, Martin DH. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. Clin Infect Dis. 2009;48(12):1649-1654.
Kisina VI, Romanova IV, Zhukova OV, Yakovlev SV. Comparative Analysis of Modern Approaches to the Treatment of M. genitalium Infection in Clinical Practice. Antibiotics and chemotherapy. 2019;(3-4):30-36. (In Russ.).
Manhart LE, Gillespie CW, Lowens MS, Khosropour CM, Colombara DV, Golden MR. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis. 2013;56 (7):934-942. 49.
Twin J, Jensen JS, Bradshaw CS., Garland SM, Fairley CK, Min LY et al. Transmission and selection of macrolide resistant Mycoplasma genitalium infections detected by rapid high resolution melt analysis. PLoS One. 2012; 7(4):e35593.
Horner P, Blee K, Adams E. Time to manage Mycoplasma genitalium as an STI: but not with azithromycin 1 g! Curr Opin Infect Dis. 2014;27(1):68-74.
Jensen JS, et al. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2016;30:1650-1656.